In The News
 
 
 

    Dana Goldman discusses his research on the economic costs and benefits of delayed aging

    February 25, 2016  "Health economist Dana Goldman from the University of Southern California has assessed the costs and health returns on delayed aging therapies.  We speak with him about how the benefits of aging outweigh the costs tenfold, and what needs to be done to ensure these economic returns. " Read More Here

    Paul Ginsburg quoted in the New York Times: "A Novel Plan for Health Care: Cutting Costs, Not Raising Them"

    February 17, 2016 In discussing a new health care plan, Paul Ginsburg pointed to the importance of a long-term contract to enable hospitals and doctors to effectively manage chronic disease. Without the assurance that patients will switch if their health plan changes or skip an appointment because of a deductible, “it makes it very difficult to engage enrollees early enough to detect their chronic diseases and manage them,” Ginsburg explained. Read More Here

    Joel Hay quoted in the LA Times on President Obama's Budget Proposal and the Implications for Health Care

    February 16, 2016  Joel Hay comments on the potential repercussions of Obama's budget proposal which includes health care proposals that could change pharmaceutical pricing and transparency in this LA Times story. Read More Here

    Geoffrey Joyce comments on the debate surrounding prescription drug prices and new initiatives cost controls in California

    October 24, 2015 "It's sort of a popular thing to say, 'I want lower drug prices,' " said Geoffrey Joyce, chairman of the pharmaceutical and health economics department at the University of Southern California School of Pharmacy. "That's like saying, 'I'm against crime,' and who's not in favor of that? But the reality is there are implications and consequences." Read More Here

    Erin Trish says the battle for market share between Anthem's new product Vivity and Kaiser is important to watch in Modern Healthcare 

    October 23, 2015 “As time unfolds, employers will have a little more sense of understanding how effective this model is in terms of controlling costs and producing high-quality outcomes for their employees,” says Erin Trish in an interview with a Modern Healthcare reporter. Read More Here

    Paul Ginsburg says the results of new study are alarming 

    October 19, 2015 Paul Ginsburg comments for the Wall Street Journal on a new study which shows outpatient medical care costs are rising.  Read More Here

    Glenn Melnick talks about a new health insurance start-up, Oscar, in LA Times

    October 18, 2015 "Innovation, in terms of consumer friendliness, is so far behind," said Glenn Melnick, a healthcare economist and professor at USC. "I am hoping they pull it off." Read More Here

    Dana Goldman and Darius Lakdawalla argue the need to move beyond price-per-dose models in a Health Affairs Blog post

    September 30, 2015 "The problem here is our creaky model of pharmaceutical pricing, which now threatens to deprive patients of these and other breakthroughs to come. For decades, the vast majority of drug manufacturers and payers have relied on pricing per dose, be it a pill, a milligram, or the like. While simple and convenient, the “price-per-dose” (PPD) model produces a number of well-known side effects that are now becoming increasingly severe," writes Goldman and Lakdawalla Read More Here 

    Dana Goldman explains "paying for value" and issue with short-terminism in healthcare in the Harvard Business Review

    September 28, 2015 "'Paying for value' is one of the most overused tropes in health care today. It is also the least well understood, because its meaning is manipulated by each stakeholder," writes Goldman Read More Here

    Darius Lakdawalla says drug price controls are not the answer in an op-ed for the New York Times' Room for Debate

    September 28, 2015
    "Our research finds that, if the U.S. government were to begin negotiating drug prices the way other governments do, drug prices would fall by about 20 percent, but innovation would fall by even more. Patients would see their lives cut short by delayed or absent drug launches. On balance, America would lose more in the form of premature mortality from price controls than it would gain in lower spending," writes Lakdawalla  Read More Here

    Paul Ginsburg gives potential upsides to the recent insurance mergers 

    September 22, 2015
    Paul Ginsburg is quoted in the LA Times about health insurance mergers after testifying at a Senate hearing on the subject. 

    Joel Hay on the role generics play in the Pharmaceutical Market

    September 4, 2015
    Joel Hay is quoted in the LA Times about the important role generics play in keeping prescription prices in balance.  Read More Here

     Paul Ginsburg on the complicated nature of insurance markets
    September 3, 2015
    Paul Ginsburg is quoted in Bloomberg Businessweek about the complicated and challenging nature of insurance markets for a new start-up insurance company like Oscar.  Read More Here

    Paul Ginsburg on a new trend in Cancer Care center growth

    September 2, 2015
    “It’s likely that [the expansion is] going to be a mixed bag,” in terms of consumer cost said Paul Ginsburg.  “It’s going to help be able to meet growth and demand and serve more patients in a convenient way. But it’s likely to overshoot. In other words, we may build beyond the capacity we need, and that could add to costs.” Read More Here